Generated by AI
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for heart disease. The company’s current pipeline centers on gene therapy programs such as TN-201 for MYBPC3-associated hypertrophic cardiomyopathy and TN-401 for PKP2-associated arrhythmogenic right ventricular cardiomyopathy, along with TN-301, a small molecule HDAC6 inhibitor being studied for heart failure with preserved ejection fraction. Tenaya Therapeutics also works through integrated platforms in gene therapy, cellular regeneration, and precision medicine to address the underlying drivers of inherited and other cardiovascular conditions. Headquartered in South San Francisco, California, the company serves the healthcare and biotechnology markets through research, discovery, and clinical development of cardiovascular treatments.
Website171 Oyster Point Boulevard
South San Francisco, CA, 94080
United States
The latest articles about TNYA.
Detailed price information for Tenaya Therapeutics Inc (TNYA-Q) from The Globe and Mail including charting and trades.
Summary of Nov 16's posts. Generated by AI.
Summary of Oct 20's posts. Generated by AI.
Summary of Dec 10's posts. Generated by AI.
Summary of Oct 20's posts. Generated by AI.
Investors talking about TNYA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.